Workflow
神经调节
icon
Search documents
研判2025!中国神经调节行业产业链、市场规模及重点企业分析:以精准神经调控革新治疗范式,重塑患者生活质量新标准[图]
Chan Ye Xin Xi Wang· 2025-10-10 01:33
Core Insights - Neuromodulation technology shows significant advantages in treating neurological diseases such as epilepsy and Parkinson's disease, enhancing treatment effectiveness and improving patients' quality of life [1][8] - The Chinese neuromodulation industry is projected to reach a market size of approximately 2.285 billion yuan in 2024, reflecting a year-on-year growth of 8.65%, driven by technological innovation and market demand [1][8] Industry Overview - Neuromodulation is a treatment method that regulates nervous system activity through electrical, magnetic, chemical, or other forms of stimulation, aiming to alleviate symptoms and improve functionality [2] - The industry can be categorized into invasive and non-invasive techniques, each comprising various specific technologies [2] Industry Development History - The Chinese neuromodulation industry has evolved over seventy years, starting from foundational research in the 1950s to the current stage of mature expansion, with significant milestones in technology introduction and innovation [2][3] - Key developments include the first DBS surgery in 1998 and the establishment of the first domestic DBS product registration in 2013, marking a shift from technology importation to independent innovation [2][3] Market Size - The neuromodulation market is expected to grow to approximately 2.285 billion yuan in 2024, with an 8.65% increase from the previous year, indicating a dual driving effect of technology transformation and market demand [1][8] Key Companies - Beijing Pincai Medical holds over 25% of the domestic market share with its comprehensive range of neuromodulation products, including DBS and SCS [9][10] - Suzhou Jingyu Medical is a leading player in the DBS field, having received FDA breakthrough device designation for its dual-target DBS technology [10][11] Industry Development Trends 1. Continuous integration of technological innovations will drive precision and intelligent upgrades in the neuromodulation sector, with advancements in AI and brain-computer interfaces expected to enhance treatment efficacy [12] 2. Application scenarios are expanding from traditional disease treatment to cognitive enhancement and emotional regulation, with consumer-grade neuromodulation devices anticipated to see explosive growth [13][14] 3. Policy and industry collaboration will promote domestic production and global expansion, with ongoing government support for brain science initiatives and the inclusion of neuromodulation procedures in insurance reimbursement [15]
获批FDA IDE!自适应脑深部刺激DBS
思宇MedTech· 2025-02-06 15:00
2025年2月6日,神经调节领域的创新企业 Newronika 宣布 开发的 自适应深部脑刺激(DBS)系统 获得美国食品药品监督管理局(FDA)的研究用器械豁 免(IDE)许可。 ▲图片源自公司官网 # N e w r o n i k a的A l p h a D BS系统:智能化深脑刺激新选择 Newronika 的 AlphaDBS 系统是一种创新的自适应深部脑刺激(aDBS)技术,主要用于治疗帕金森病等运动障碍疾病。该系统的核心特点包括: AlphaDBS系统 主要针对帕金森病等运动障碍疾病。帕金森病是一种常见的神经退行性疾病,目前的治疗方法主要包括 药物治疗 和 传统的深部脑刺激 (DBS)技术 。传统DBS系统以固定参数持续刺激大脑特定区域,无法根据症状变化进行调整。这可能导致过度刺激的副作用或刺激不足导致症状恶化 。 # 临床试验结果 1 . 实时反馈机制: 通过持续监测患者的脑信号(局部场电位,LFPs)来优化治疗方案。 2. 自动调节刺激: 根据患者实时状态自动调整刺激参数,提高治疗精准度。 3. 双模式操作: 可在传统的持续刺激(cDBS)和自适应刺激(aDBS)模式之间切换。 4. 先进的 ...